Marcella Fassò

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens, Cristina Cruz, Joseph P. Eder et al. · JAMA Oncology · 2018 · 793 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

David F. McDermott, Jeffrey A. Sosman, Mario Sznol et al. · Journal of Clinical Oncology · 2016 · 558 citations

Medicine, Oncology, Pharmacology +17

Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy

Rebecca Waitz, Stephen B. Solomon, Elena N. Petre et al. · Cancer Research · 2011 · 278 citations · Full text

Life Sciences, Immunology, Oncology +17

Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)

Leisha A. Emens, Fadi S. Braiteh, Philippe A. Cassier et al. · Cancer Research · 2015 · 210 citations

Medicine, Oncology, Pharmacology +17

CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

Mahrukh Huseni, Lifen Wang, Joanna E. Klementowicz et al. · Cell Reports Medicine · 2023 · 183 citations · Full text

Life Sciences, Immunology, Oncology +17